PharmaIN Corporation Announces Attendance at the 2019 J.P. Morgan Healthcare Conference.

Press Release

PharmaIN Corporation Announces Attendance at the 2019 J.P. Morgan Healthcare Conference. 

 

Bothell, WA, USA – 4 December 2018  PharmaIN Corporation announced its attendance at the J.P. Morgan Healthcare Conference, the largest and most informative healthcare investment symposium in the industry. This three-day event will be held on January 7-10, 2019 at the Westin St. Francis Hotel in San Francisco, California.  

Elijah Bolotin, CEO and founder, and Mark Edelsward, Director of Business Development, will be meeting with current and prospective collaborators during the conference.  

Please contact Mark Edelsward if PharmaIN’s half-life extension technologies are of interest and you would like to arrange a meeting. 

About the Conference 

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. 

 About PharmaIN 

PharmaIN Corporation, headquartered in Bothell, WA, (near Seattle) is developing superior drug therapies by using its “Protected Graft Co-polymer” (PGC™) excipient and innovative peptide engineering technologies to enable effective and safe injectable peptide therapeutics. Besides peptides, PGC excipient can be beneficial to improve PK, bioavailability, stability and solubility of numerous proteins and some poorly soluble potent small molecules. PharmaIN works with partner companies to enable new, value-added drug therapies and improve “old” drugs using these platforms. Visit www.PharmaIN.com.